FeverNCT00259142
Acceptability and Cost Effectiveness of Home Based Management of Fever: Different Strategies
A study testing Chloroquine, sulphadoxine-pyrimethamine in people with Fever and Anaemia, run by DBL -Institute for Health Research and Development at 1 site in Uganda.
Trial summary
Malaria remains a major cause of morbidity and mortality particularly among children < 5 years in Uganda. Due to inaccessibility many children die before they reach the health facility. Read more about this study
- Who is it for?
- Ages Up to 59 months
- What is being tested?
- Chloroquine, sulphadoxine-pyrimethamine
- How many people
- 1,314 participants
- Where
- 1 siteUganda
- Study dates
- Nov 2005to Nov 2005
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Up to 59 months
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- children 0-59 months with fever
Who cannot join
None listed.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Community Acceptability and Cost-effectiveness of Two Drug Distribution Methods for Home Based Management of Fevr in Kayunga District, Uganda
Malaria remains a major cause of morbidity and mortality particularly among children < 5 years in Uganda. Due to inaccessibility many children die before they reach the health facility. The Home Based Management of Fever (HBMF) strategy was adopted in Uganda as a mean to improve access to early and appropriate treatment of fever at community level. Pre-packed chloroquine with sulphadoxine-pyrimethamine (HOMAPAK) is provided through Community Drug Distributors(CDDs). Initial evaluation showed underutilization of the CDDs (15%). This cast doubt on community acceptability, accessibility as well as its feasibility and cost effectiveness. This 3-year project intends to compare community acceptability and cost effectiveness of two HOMAPAK distribution methods. The current CDD-based HOMAPAK distribution versus home-based HOMAPAK distribution. The study hypothesis is that "home-based HOMAPAK distribution is more acceptable to the community and more cost effective than the CDD based HOMAPAK A non randomised community study will be conducted in two sub-counties of Mukono district. In the control arm, HOMAPAKs will be distributed through the CDDs while in the intervention arm, HOMAPAKs will be directly distributed to the caretakers in the homes. The study population are caretakers and their children < 5 years. At baseline a survey (Phase 1) with a sample size 657 in each study area will assess the common drugs stocked at home to treat malaria and the health seeking behaviour for malaria for children < 5 years and to determine the prevalence of malaria parasitaemia and anaemia among children < 5 years. Phase 2 includes the intervention. The villages will be assigned to either the control or intervention arm. Anaemia and malaria parasitaemia among children with fever will be assessed through active case finding. The impact of either distribution system on accessibility, acceptability, sustainability, compliance, cost effectiveness and malaria morbidity will be assessed during the evaluation phase. Health education messages on malaria prevention and treatment will be given to both communities. Drug misuse will be limited by distributing HOMAPAKs according to the number of children <5years in each household. HOMAPAK will only be replenished after the caretaker returns a used packet to the CDD.
Read the detailed description
The hypothesis is that distributing HOMAPAK directly to caretakers is more acceptable to the community, cost effective and results in reduced malaria morbidity among children < 5 years than distribution through CDDs.
General Objective:
To compare the communities malaria seeking behaviour in the two drug distribution methods of HOMAPAK in order to provide information that can be used to enhance the HBMF strategy.
Specific Objectives:
- To assess trends in the types and numbers of antimalarials stocked for use among children < 5 years in the two study areas
- To assess the patterns of health seeking behaviour in the community for fever among children under five years of age.
- To assess the incidence of malaria, and the associated morbidity (anaemia) in the two study areas.
- To compare community acceptability of the two drug distribution methods of HOMAPAK in the aspects of, utilisation of the services, drug compliance, coverage and accessibility.
- To assess the cost and compare cost effectiveness of the two drug distribution methods of the HOMAPAK on malaria morbidity in the community. Study area and population: The study will be conducted in Kayunga district, located 80 km northeast of Kampala with a total population of 800000 (Uganda Housing and Population Census, 2002) of which 20 % is < 5 years. It is hyperendemic for malaria. The study population will consist of the children < 5 years and their caretakers. The study areas will be those without HOMAPAK being distributed at all. Study design: Household based intervention study. Two drug distribution methods of HOMAPAK will be compared. In the Control arm, HOMAPAKs will be distributed through the conventional HOMAPAK distribution method (i.e through the CDDs) while in the Intervention arm, HOMAPAKs will be distributed directly to the caretakers. A Baseline survey will assess the patterns of health seeking behaviour for the < 5 children with fever. Types of antimalarials stocked in homes will be established. The prevalence of malaria and anaemia among children < 5 years will be established. In the intervention phase the two different HOMAPAK distribution methods will be implemented and monitored. Active case finding of malaria cases will be combined with passive surveillance. A structured questionnaire will be administered to the caretakers and a finger prick blood sample for Hb and malaria parasitaemia will be drawn from the children. Malaria records at the health facility will be reviewed for number of malaria cases seen and their clinical outcome. In the evaluation phase the impact of the drug distribution methods on antimalarials stocked in the homes,health seeking behaviour and other outcome measures. Sample size: Baseline and evaluation phase The sample size (n) has been estimated according to Kirkwood and Sterne (2003) for comparing of two means. The required sample size is 597 per group. To cater for loss of follow up, 10 % of the sample size will be added thus giving a total of 657 per group. Methods The Intervention Phase The study populations will consist of the caretakers and children under five years of age in the Control and the Intervention arms. Two CDDs in each village will be trained and given HOMAPAKs. In the Control Arm the CDDs will keep the HOMAPAKs and will only be distributed when the caretakers seek care for their children. In contrast in the intervention area, the CDDs will distribute the drugs to all homes with children < 5 years of age. The CDDs will only act as RELAY POINTS for the HOMAPAKs. All villages of the study parishes in either arm will be included. Activities: Community sensitisation/selection of the CDDs Through village meetings the community will be informed about the project and be requested to select two people for training as CDDs. Two district trainers will conduct a training workshop. Item included: the roles of the CDD, issues about malaria (its importance, cause, clinical presentation, case management \& prevention), HOMAPAK dosage, counselling (preventive, compliance), referral of cases, record keeping (HMIS, drug stocks), recognition of a child with fever and what to do for her/him, determining what pre-pack to give, recording the treatment and drug storage. Procurement and distribution of HOMAPAK HOMAPAKs will be procured through the MoH and supplied to all CDDs in both study communities. The CDDs in the control arm will only give the drugs when the caretakers seek care, while those in intervention arm will distribute the appropriate HOMAPAKs to all HH with children < 5 years. In order to prevent drug misuse, the CDDs in the intervention group will be instructed to only replenish the stocks in the household after the caretaker produces the used packet of HOMAPAK. Monitoring cases of malaria Three field assistants (FAs) will be stationed in the community and will do weekly surveys in households with children with either malaria or history of fever in the previous 7 days. A case of malaria will be any child, who either currently has a fever (axillary temperature >37.5 C) and any parasitaemia) or has a history of fever in 48 hours prior to the survey plus any parasitaemia. Information regarding health-seeking behaviour by the caretaker for the child with fever and related costs will be obtained by use of a questionnaire. Finger prick blood samples for Hb and malaria parasitaemia will be taken from the child. The Hb will be obtained by use of a portable haemoglobin photometer (HemoCue) while a thick malaria slide will be examined under a microscope. The FAs will give appropriate information regarding malaria control and treatment to the caretakers. Monitoring and Supervision of project activities Project activities will be monitored and supervised by the project staff , the district health team, and the community themselves. The project staff will join the district team during their quarterly support supervision visits. The PI and the district supervisor will do fortnightly supervision in the study area. During the supervisory visits, meetings with the CDDs and community leaders will be held to discuss the progress of the project activities. Meetings will also be held with the FAs and Field Supervisors. Patient records and drug stock cards at both the health facility and CDDs will be reviewed. The Evaluation Phase: To assess the impact of the distribution methods on patterns of health seeking behaviour of the caretakers for fever among children < 5 years, acceptability and related costs for the household and government, antimalarials stocked in the homes, malaria morbidity among children < 5 years, a second KAP Survey will be conducted 2 years after the implementation of the project, in the same villages, on a comparable sample of 657 caretakers and children < 5 years in each study area using the same structured questionnaire and FGD guide. Sampling: Two sub counties (SC) in the district with similar demographic and socio-economic characteristics will be purposely selected. 50% of the parishes in each SC will then be randomly selected. Baseline and Evaluation phase: In order to have at least 30 households (HH) in a village, a total of 17 villages will be selected from the sampled parishes in each sub county using probability proportionate to size sampling. At village level the list of all the HH in the village will be obtained from the chairman of the village. The 30HH will be selected randomly. Appointments will be made with the caretakers to agree on the time for the interview. In case the caretakers refuse to participate, she will not be replaced. In case the selected HH does not have a child < 5 years, it will be replaced by one in the neighbourhood with such a child. In case there is more than one eligible caretaker in the selected HH like in polygamous homes, then one respondent will be selected by use of the ballot method. A similar procedure will be applied in case there is more than one eligible child in the HH. After seeking an informed consent from the respondent, an interview will be conducted.Participants for the FGDs will be purposely selected from the parishes HH that will not be part of the structured questionnaire. Two FGDs for men and Two for women will be conducted separately. Intervention phase: All households with children < 5 years in the study villages in both the control and intervention arm Outcome Measures: Patterns of health seeking behaviour
- Types of health services used, factors affecting utilisation of the formal health services (individual, community, health system based etc) Utilisation of antimalarial in the community
- Types of antimalarial drugs used for the malaria among the under five children
- Number of antimalarial drugs used to treatment an episode of fever
- % change in types and number of antimalarial drugs stocked in the homes Acceptability
- Proportion of under-five children with fever that are given HOMAPAKS
- Proportion of caretakers that use HOMAPAKS as their first choice of treatment for fever
- Proportion of caretakers that are able to correctly use HOMAPAKs Accessibility
- Proportion of children that get treatment with HOMAPAK within 24 hours of onset of fever
- % of weeks in the year without stock-outs of HOMAPAKs
- % of drug distributors that are always available
- % of households with HOMAPAKS for future episodes of fever Feasibility/Sustainability
- % of distributors/households with satisfactory drug storage,% of households with expired HOMAPAK Compliance
- Proportion of febrile under-five children that get appropriate treatment
- % of caretakers that show correct dosage for the child
- % of under-five children that are given HOMAPAK for only fever/malaria
- proportion of under five that get appropriate referral Coverage
- Proportion of under five children with fever that get treatment with HOMAPAK Cost \& cost-effectiveness
- Average costs incurred by MoH to deliver HOMAPAK up to HH level
- Average costs incurred by MoH in treatment of a severe malaria case in a health facility
- Average Costs incurred by a house hold level to seek care for a case of malaria
- Average cost by a household to treat a case of severe malaria at a health facility
- Cost effective ratio for a case of severe malaria averted at health facility level
- Cost effective ratio for a case of blood transfusion averted at health facility level Malaria morbidity
- % increase in mean Hb levels
- % decrease in prevalence and intensity of parasitaemia
- % decrease in severe malaria cases (HIS)
- Being tested
- Chloroquine, sulphadoxine-pyrimethamine
- Keywords
- home management of fever, malaria, Uganda
- Medical subject headings
- Fever, Anemia, Malaria
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Chloroquine, sulphadoxine-pyrimethamineDrug
What is being measured
The primary outcome is the main question the study is designed to answer.
See detailed description
Secondary outcomes (1)
See detailed description
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Nov 2005 (estimated)
- Study startNov 2005
- Primary completionNov 2005
- Study completionNov 2005
Why it stopped: Study never started
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for FeverStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 1,314 participants (estimated)
Sponsor and investigators
- Lead sponsor
- DBL -Institute for Health Research and Development
- Sponsor type
- University, hospital or other
- Collaborators
- World Health Organization, Institute for Epidemiology and Social Medicine, Aarhus University, Denmark
- Investigators
- Robinah Najjembe, MD, MPH, Principal investigator, Makerere University Institute of Public Health
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00259142
- Sponsor's protocol ID
- UGA.5.2RNA2005
- Status last verified
- May 2015
- First submitted
- 25 Nov 2005
- Last updated
- 13 May 2015
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 13 May 2015. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Community Acceptability and Cost-effectiveness of Two Drug Distribution Methods for Home Based Management of Fevr in Kayunga District, Uganda
- ClinicalTrials.gov ID
- NCT00259142
- Acronym / sponsor ID
- UGA.5.2RNA2005
- Keywords
- home management of fever, malaria, Uganda
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: Study never started
- Enrolment
- 1,314 participants (estimated)
- Lead sponsor
- DBL -Institute for Health Research and DevelopmentUniversity, hospital or other
- Collaborators
- World Health Organization, Institute for Epidemiology and Social Medicine, Aarhus University, Denmark
- Study start
- Nov 2005
- Primary completion
- Nov 2005 (actual)
- Study completion
- Nov 2005 (actual)
- First posted
- 29 Nov 2005 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Malaria remains a major cause of morbidity and mortality particularly among children < 5 years in Uganda. Due to inaccessibility many children die before they reach the health facility. The Home Based Management of Fever (HBMF) strategy was adopted in Uganda as a mean to improve access to early and appropriate treatment of fever at community level. Pre-packed chloroquine with sulphadoxine-pyrimethamine (HOMAPAK) is provided through Community Drug Distributors(CDDs). Initial evaluation showed underutilization of the CDDs (15%). This cast doubt on community acceptability, accessibility as well as its feasibility and cost effectiveness. This 3-year project intends to compare community acceptability and cost effectiveness of two HOMAPAK distribution methods. The current CDD-based HOMAPAK distribution versus home-based HOMAPAK distribution. The study hypothesis is that "home-based HOMAPAK distribution is more acceptable to the community and more cost effective than the CDD based HOMAPAK A non randomised community study will be conducted in two sub-counties of Mukono district. In the control arm, HOMAPAKs will be distributed through the CDDs while in the intervention arm, HOMAPAKs will be directly distributed to the caretakers in the homes. The study population are caretakers and their children < 5 years. At baseline a survey (Phase 1) with a sample size 657 in each study area will assess the common drugs stocked at home to treat malaria and the health seeking behaviour for malaria for children < 5 years and to determine the prevalence of malaria parasitaemia and anaemia among children < 5 years. Phase 2 includes the intervention. The villages will be assigned to either the control or intervention arm. Anaemia and malaria parasitaemia among children with fever will be assessed through active case finding. The impact of either distribution system on accessibility, acceptability, sustainability, compliance, cost effectiveness and malaria morbidity will be assessed during the evaluation phase. Health education messages on malaria prevention and treatment will be given to both communities. Drug misuse will be limited by distributing HOMAPAKs according to the number of children <5years in each household. HOMAPAK will only be replenished after the caretaker returns a used packet to the CDD.
Detailed description
The hypothesis is that distributing HOMAPAK directly to caretakers is more acceptable to the community, cost effective and results in reduced malaria morbidity among children < 5 years than distribution through CDDs.
General Objective:
To compare the communities malaria seeking behaviour in the two drug distribution methods of HOMAPAK in order to provide information that can be used to enhance the HBMF strategy.
Specific Objectives:
- To assess trends in the types and numbers of antimalarials stocked for use among children < 5 years in the two study areas
- To assess the patterns of health seeking behaviour in the community for fever among children under five years of age.
- To assess the incidence of malaria, and the associated morbidity (anaemia) in the two study areas.
- To compare community acceptability of the two drug distribution methods of HOMAPAK in the aspects of, utilisation of the services, drug compliance, coverage and accessibility.
- To assess the cost and compare cost effectiveness of the two drug distribution methods of the HOMAPAK on malaria morbidity in the community. Study area and population: The study will be conducted in Kayunga district, located 80 km northeast of Kampala with a total population of 800000 (Uganda Housing and Population Census, 2002) of which 20 % is < 5 years. It is hyperendemic for malaria. The study population will consist of the children < 5 years and their caretakers. The study areas will be those without HOMAPAK being distributed at all. Study design: Household based intervention study. Two drug distribution methods of HOMAPAK will be compared. In the Control arm, HOMAPAKs will be distributed through the conventional HOMAPAK distribution method (i.e through the CDDs) while in the Intervention arm, HOMAPAKs will be distributed directly to the caretakers. A Baseline survey will assess the patterns of health seeking behaviour for the < 5 children with fever. Types of antimalarials stocked in homes will be established. The prevalence of malaria and anaemia among children < 5 years will be established. In the intervention phase the two different HOMAPAK distribution methods will be implemented and monitored. Active case finding of malaria cases will be combined with passive surveillance. A structured questionnaire will be administered to the caretakers and a finger prick blood sample for Hb and malaria parasitaemia will be drawn from the children. Malaria records at the health facility will be reviewed for number of malaria cases seen and their clinical outcome. In the evaluation phase the impact of the drug distribution methods on antimalarials stocked in the homes,health seeking behaviour and other outcome measures. Sample size: Baseline and evaluation phase The sample size (n) has been estimated according to Kirkwood and Sterne (2003) for comparing of two means. The required sample size is 597 per group. To cater for loss of follow up, 10 % of the sample size will be added thus giving a total of 657 per group. Methods The Intervention Phase The study populations will consist of the caretakers and children under five years of age in the Control and the Intervention arms. Two CDDs in each village will be trained and given HOMAPAKs. In the Control Arm the CDDs will keep the HOMAPAKs and will only be distributed when the caretakers seek care for their children. In contrast in the intervention area, the CDDs will distribute the drugs to all homes with children < 5 years of age. The CDDs will only act as RELAY POINTS for the HOMAPAKs. All villages of the study parishes in either arm will be included. Activities: Community sensitisation/selection of the CDDs Through village meetings the community will be informed about the project and be requested to select two people for training as CDDs. Two district trainers will conduct a training workshop. Item included: the roles of the CDD, issues about malaria (its importance, cause, clinical presentation, case management \& prevention), HOMAPAK dosage, counselling (preventive, compliance), referral of cases, record keeping (HMIS, drug stocks), recognition of a child with fever and what to do for her/him, determining what pre-pack to give, recording the treatment and drug storage. Procurement and distribution of HOMAPAK HOMAPAKs will be procured through the MoH and supplied to all CDDs in both study communities. The CDDs in the control arm will only give the drugs when the caretakers seek care, while those in intervention arm will distribute the appropriate HOMAPAKs to all HH with children < 5 years. In order to prevent drug misuse, the CDDs in the intervention group will be instructed to only replenish the stocks in the household after the caretaker produces the used packet of HOMAPAK. Monitoring cases of malaria Three field assistants (FAs) will be stationed in the community and will do weekly surveys in households with children with either malaria or history of fever in the previous 7 days. A case of malaria will be any child, who either currently has a fever (axillary temperature >37.5 C) and any parasitaemia) or has a history of fever in 48 hours prior to the survey plus any parasitaemia. Information regarding health-seeking behaviour by the caretaker for the child with fever and related costs will be obtained by use of a questionnaire. Finger prick blood samples for Hb and malaria parasitaemia will be taken from the child. The Hb will be obtained by use of a portable haemoglobin photometer (HemoCue) while a thick malaria slide will be examined under a microscope. The FAs will give appropriate information regarding malaria control and treatment to the caretakers. Monitoring and Supervision of project activities Project activities will be monitored and supervised by the project staff , the district health team, and the community themselves. The project staff will join the district team during their quarterly support supervision visits. The PI and the district supervisor will do fortnightly supervision in the study area. During the supervisory visits, meetings with the CDDs and community leaders will be held to discuss the progress of the project activities. Meetings will also be held with the FAs and Field Supervisors. Patient records and drug stock cards at both the health facility and CDDs will be reviewed. The Evaluation Phase: To assess the impact of the distribution methods on patterns of health seeking behaviour of the caretakers for fever among children < 5 years, acceptability and related costs for the household and government, antimalarials stocked in the homes, malaria morbidity among children < 5 years, a second KAP Survey will be conducted 2 years after the implementation of the project, in the same villages, on a comparable sample of 657 caretakers and children < 5 years in each study area using the same structured questionnaire and FGD guide. Sampling: Two sub counties (SC) in the district with similar demographic and socio-economic characteristics will be purposely selected. 50% of the parishes in each SC will then be randomly selected. Baseline and Evaluation phase: In order to have at least 30 households (HH) in a village, a total of 17 villages will be selected from the sampled parishes in each sub county using probability proportionate to size sampling. At village level the list of all the HH in the village will be obtained from the chairman of the village. The 30HH will be selected randomly. Appointments will be made with the caretakers to agree on the time for the interview. In case the caretakers refuse to participate, she will not be replaced. In case the selected HH does not have a child < 5 years, it will be replaced by one in the neighbourhood with such a child. In case there is more than one eligible caretaker in the selected HH like in polygamous homes, then one respondent will be selected by use of the ballot method. A similar procedure will be applied in case there is more than one eligible child in the HH. After seeking an informed consent from the respondent, an interview will be conducted.Participants for the FGDs will be purposely selected from the parishes HH that will not be part of the structured questionnaire. Two FGDs for men and Two for women will be conducted separately. Intervention phase: All households with children < 5 years in the study villages in both the control and intervention arm Outcome Measures: Patterns of health seeking behaviour
- Types of health services used, factors affecting utilisation of the formal health services (individual, community, health system based etc) Utilisation of antimalarial in the community
- Types of antimalarial drugs used for the malaria among the under five children
- Number of antimalarial drugs used to treatment an episode of fever
- % change in types and number of antimalarial drugs stocked in the homes Acceptability
- Proportion of under-five children with fever that are given HOMAPAKS
- Proportion of caretakers that use HOMAPAKS as their first choice of treatment for fever
- Proportion of caretakers that are able to correctly use HOMAPAKs Accessibility
- Proportion of children that get treatment with HOMAPAK within 24 hours of onset of fever
- % of weeks in the year without stock-outs of HOMAPAKs
- % of drug distributors that are always available
- % of households with HOMAPAKS for future episodes of fever Feasibility/Sustainability
- % of distributors/households with satisfactory drug storage,% of households with expired HOMAPAK Compliance
- Proportion of febrile under-five children that get appropriate treatment
- % of caretakers that show correct dosage for the child
- % of under-five children that are given HOMAPAK for only fever/malaria
- proportion of under five that get appropriate referral Coverage
- Proportion of under five children with fever that get treatment with HOMAPAK Cost \& cost-effectiveness
- Average costs incurred by MoH to deliver HOMAPAK up to HH level
- Average costs incurred by MoH in treatment of a severe malaria case in a health facility
- Average Costs incurred by a house hold level to seek care for a case of malaria
- Average cost by a household to treat a case of severe malaria at a health facility
- Cost effective ratio for a case of severe malaria averted at health facility level
- Cost effective ratio for a case of blood transfusion averted at health facility level Malaria morbidity
- % increase in mean Hb levels
- % decrease in prevalence and intensity of parasitaemia
- % decrease in severe malaria cases (HIS)
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
Who may qualify
- Ages
- Up to 59 months
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (1 listed)
- children 0-59 months with fever
Key exclusion criteria (0 listed)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Chloroquine, sulphadoxine-pyrimethamine | Drug | – |
Primary outcome
See detailed description
1 secondary outcome
See detailed description
Results and safety
The study was stopped early (reason given: Study never started). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 May 2015.
- Related InfoLink provided by the sponsor.
Related trials for Fever
Recruiting
Assessment of Communication Interventions on Vaccination Knowledge and Acceptance
Vaccination Knowledge and Acceptance, Informed Vaccine-decision Making
RecruitingObservational study
Natural History of Trisomy 8-Associated Autoinflammatory Disease (TRIAD) and Related Disorders
Trisomy 8 Mosaicism, Trisomy 8 Associated Autoinflammatory Disease
RecruitingObservational study
Familial Mediterranean Fever and Related Disorders: Genetics and Disease Characteristics
Familial Mediterranean Fever (FMF), Autoinflammation
RecruitingPhase 1
Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies
Peritoneal Mesothelioma, Peritoneal Carcinomatosis
Recruiting
Recovery After Fatigue in Young Athletes: Comparison Between TECAR Therapy and Cycle Ergometer"
Muscle Fatigue, Healthy Adult
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Robinah Najjembe, MD, MPH principal investigator
Makerere University Institute of Public Health
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Chloroquine, sulphadoxine-pyrimethamine in people with Fever and Anaemia, run by DBL -Institute for Health Research and Development at 1 site in Uganda.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 13 May 2015. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Uganda. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was stopped early (reason given: Study never started). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
See detailed description. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 May 2015.